LANN-study: Lantus, Amaryl, Novorapid, Novomix Study
Diabetes Mellitus Type II
About this trial
This is an interventional treatment trial for Diabetes Mellitus Type II focused on measuring diabetes, failing oral treatment, weight gain
Eligibility Criteria
Inclusion Criteria: failing maximal oral treatment, defined as mean fasting blood glucose over 8 mmol/l and HbA1C over 7.5% for three months or more BMI 25 - 35 kg/m2 fasting plasma C-peptide level over 0.3 nmol/l stable metformin and sulfonylurea dose for at least three months stable weight for at least three months (change maximal 2 kg) Exclusion Criteria: fasting glucose over 25 mmol/l use of alpha-glucosidase inhibitors or thiazolidinediones in the two months preceding the study renal or liver failure defined as serum creatinine over 150 micromol/l, liver enzymes over 1.5 upper normal limit heart failure pregnancy alcohol more than two units per day inflammatory or infectious diseases unstable chronic disease discontinuation of smoking within three months of randomisation date allergy for or intolerance of glimepiride or novorapid.
Sites / Locations
- Rijnstate Hospital